| Revenue growth | 48% YoY growth for 9M FY'26 reaching ₹426 crores. |
|---|---|
| Margins | EBITDA margin improved to 16% in Q3, up 384 bps. |
| Demand visibility | Strong traction in new brands launched over last 3 years. |
| Management confidence | High; MD emphasizes overachieving conservative internal targets. |
Growth
Q3 Revenue: ₹160.92cr (+57% YoY); 9M Revenue: ₹426cr (+48% YoY). 9M PAT: ₹26.98cr (+96% YoY).
Outlook
Targets 51% revenue from new-age business by 2029-2030; expects 12-18% growth in legacy business.
Risks
Seasonal Q1 weakness; rising finance costs due to working capital needs and new machinery loans.
Last quarter's promises, checked
Delivered
- Legacy business growth 12-18% → delivered ~15-20% (= BEAT)
- New-age growth 20-25% → delivered ~20-25% (= BEAT)
- Full year revenue target ₹550-600cr → on track with 9M ₹426cr (= BEAT)
Partly delivered
- Pet biscuit line start Q3 → production started, revenue impact expected Q4 (= PARTIAL)
Earnings Call filed with BSE, NSE: FREDUN. Summary written with AI assistance from the document.
Fredun Pharmaceuticals Ltd: key numbers
- Share price
- ₹1,360.90
- Market cap
- ₹1,944 Cr
- Revenue (annual)
- ₹635.5 Cr
- Net profit (annual)
- ₹32.62 Cr
- P/E (TTM)
- 44.4×Sector 50.4×
- Promoter holding
- 44.57%+0.40% QoQ
- FII holding
- 1.06%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Fredun Pharmaceuticals Ltd
All →Fredun Pharmaceuticals Capital Structure Change
Fredun Pharmaceuticals allotted 3,61,599 equity shares following the conversion of 1,20,533 warrants. This allotment was executed at an issue price of Rs. 1,250 per warrant.
- Value
- ₹15.07 Cr
Fredun Pharmaceuticals Acquisition Worth ₹300 Cr
Fredun Pharmaceuticals acquired a 26% stake in ₹300 Crore-valued Goodman Vetcare, a dedicated pet pharmacy chain. Plans target PAN-India expansion with ~₹100 Cr revenue by FY31.
- Value
- ₹300.0 Cr
- new pet pharmacy stores planned
- 8.0 stores
Fredun Pharmaceuticals Board Meeting Outcome
Fredun Pharmaceuticals allotted 2,71,200 equity shares following the conversion of 90,400 warrants. The board approved the issuance, raising Rs 11.3 Crore in total consideration.
- Value
- ₹11.30 Cr
Fredun Pharmaceuticals Business Update
Fredun Pharmaceuticals announced expansion of its Furlicks pet wellness range from 6 to 22 SKUs. The press release signals accelerated growth in the pet wellness segment.
Fredun Pharmaceuticals Acquisition
Fredun Pharmaceuticals acquires pet-wellness brand Furlicks from USV and Wellbeing Nutrition. The deal marks strategic entry into India's pet-wellness market with plans to launch 44 new SKUs.
Fredun Pharmaceuticals Product Launch
Fredun Pharmaceuticals launched PAWTALKS, a digital knowledge platform for pet and animal healthcare. Initially debuting on YouTube and Instagram, it connects veterinary experts with pet owners.